Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Regulus Therapeutics Inc.

    NASDAQ: RGLS · Real-Time Price · USD
    8.11
    0.16 (2.01%)
    At close: Jun 05, 2025, 3:59 PM
    8.13
    0.31%
    After-hours: Jun 05, 2025, 07:47 PM EDT

    Regulus Therapeutics Statistics

    Share Statistics

    Regulus Therapeutics has 69.23M shares outstanding. The number of shares has increased by 1.19% in one year.

    Shares Outstanding

    n/a
    		 69.23M

    Shares Change (YoY)

    n/a
    		 1.19%

    Shares Change (QoQ)

    n/a
    		 1.13%

    Owned by Institutions (%)

    n/a
    		 81.73%

    Shares Floating

    n/a
    		 n/a

    Failed to Deliver (FTD) Shares

    n/a
    		 3,821

    FTD / Avg. Volume

    n/a
    		 0.19%

    Short Selling Information

    The latest short interest is 1.91M, so 2.76% of the outstanding shares have been sold short.

    Short Interest

    n/a
    		 1.91M

    Short % of Shares Out

    n/a
    		 2.76%

    Short % of Float

    n/a
    		 3.5%

    Short Ratio (days to cover)

    n/a
    		 1.14

    Valuation Ratios

    The PE ratio is -1.92 and the forward PE ratio is -7.49. Regulus Therapeutics's PEG ratio is 0.04.

    PE Ratio

    n/a
    		 -1.92

    Forward PE

    n/a
    		 -7.49

    PS Ratio

    n/a
    		 0

    Forward PS

    n/a
    		 0.8

    PB Ratio

    n/a
    		 1.17

    P/FCF Ratio

    n/a
    		 -2.12

    PEG Ratio

    n/a
    		 0.04
    Financial Ratio History

    Enterprise Valuation

    Currently the Enterprise Value (EV) is not available for Regulus Therapeutics.

    EV / Sales

    n/a
    		 n/a

    EV / EBITDA

    n/a
    		 n/a

    EV / EBIT

    n/a
    		 n/a

    EV / FCF

    n/a
    		 n/a

    Financial Position

    The company has a current ratio of 10.98, with a Debt / Equity ratio of 0.

    Current Ratio

    n/a
    		 10.98

    Quick Ratio

    n/a
    		 10.98

    Debt / Equity

    n/a
    		 0

    Debt / EBITDA

    n/a
    		 -0.01

    Debt / FCF

    n/a
    		 -0.01

    Interest Coverage

    n/a
    		 -316.71

    Financial Efficiency

    Return on Equity is n/a and Return on Invested Capital is n/a.

    Return on Equity

    n/a
    		 n/a

    Return on Assets

    n/a
    		 n/a

    Return on Invested Capital

    n/a
    		 n/a

    Revenue Per Employee

    n/a
    		 n/a

    Profits Per Employee

    n/a
    		 $-1,363,470.59

    Employee Count

    n/a
    		 34

    Asset Turnover

    n/a
    		 0

    Inventory Turnover

    n/a
    		 n/a

    Taxes

    Income Tax

    n/a
    		 1K

    Effective Tax Rate

    n/a
    		 0%

    Stock Price Statistics

    The stock price has increased by 237.97% in the last 52 weeks. The beta is 0.37, so Regulus Therapeutics's price volatility has been higher than the market average.

    Beta

    n/a
    		 0.37

    52-Week Price Change

    n/a
    		 237.97%

    50-Day Moving Average

    n/a
    		 4.95

    200-Day Moving Average

    n/a
    		 2.34

    Relative Strength Index (RSI)

    n/a
    		 88.15

    Average Volume (20 Days)

    n/a
    		 2,012,103

    Income Statement

    Revenue

    n/a
    		 n/a

    Gross Profit

    n/a
    		 n/a

    Operating Income

    n/a
    		 -50.04M

    Net Income

    n/a
    		 -46.36M

    EBITDA

    n/a
    		 -45.85M

    EBIT

    n/a
    		 -46.2M

    Earnings Per Share (EPS)

    n/a
    		 -0.82
    Full Income Statement

    Balance Sheet

    The company has 38.53M in cash and 274K in debt, giving a net cash position of 38.25M.

    Cash & Cash Equivalents

    n/a
    		 38.53M

    Total Debt

    n/a
    		 274K

    Net Cash

    n/a
    		 38.25M

    Retained Earnings

    n/a
    		 -559.57M

    Total Assets

    n/a
    		 74.83M

    Working Capital

    n/a
    		 67.3M
    Full Balance Sheet

    Cash Flow

    In the last 12 months, operating cash flow was -41.67M and capital expenditures -340K, giving a free cash flow of -42.01M.

    Operating Cash Flow

    n/a
    		 -41.67M

    Capital Expenditures

    n/a
    		 -340K

    Free Cash Flow

    n/a
    		 -42.01M

    FCF Per Share

    n/a
    		 -0.75
    Full Cash Flow Statement

    Margins

    Gross Margin

    n/a
    		 n/a

    Operating Margin

    n/a
    		 n/a

    Pretax Margin

    n/a
    		 n/a

    Profit Margin

    n/a
    		 n/a

    EBITDA Margin

    n/a
    		 n/a

    EBIT Margin

    n/a
    		 n/a

    FCF Margin

    n/a
    		 n/a

    Dividends & Yields

    RGLS does not appear to pay any dividends at this time.

    Dividend Per Share

    n/a
    		 n/a

    Dividend Yield

    n/a
    		 n/a

    Dividend Growth (YoY)

    n/a
    		 n/a

    Payout Ratio

    n/a
    		 n/a

    Earnings Yield

    n/a
    		 n/a

    FCF Yield

    n/a
    		 n/a
    Dividend Details

    Analyst Forecast

    The average price target for RGLS is $8, which is -0.1% lower than the current price. The consensus rating is "Hold".

    Price Target

    n/a
    		 $8

    Price Target Difference

    n/a
    		 -0.1%

    Analyst Consensus

    n/a
    		 Hold

    Analyst Count

    n/a
    		 6
    Stock Forecasts

    Fair Value

    There are several formulas that can be used to estimate the intrinsic value of a stock.

    Lynch Fair Value

    n/a
    		 n/a

    Lynch Upside

    n/a
    		 n/a

    Graham Number

    n/a
    		 n/a

    Graham Upside

    n/a
    		 n/a

    Stock Splits

    The last stock split was on Jun 29, 2022. It was a backward split with a ratio of 1:10.

    Last Split Date

    n/a
    		 Jun 29, 2022

    Split Type

    n/a
    		 backward

    Split Ratio

    n/a
    		 1:10

    Scores

    Altman Z-Score

    n/a
    		 45.18

    Piotroski F-Score

    n/a
    		 2

    Add to Watchlist